Alexion co-founder will retire in January

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) and we will feature it here at the end of each week.

Alexion co-founder will retire in January

Alexion ($ALXN) announced that Stephen Squinto, the company's co-founder and chief global operations officer, will be retiring in January. Current senior vice president and general manager for Ireland Julie O'Neill will succeed Squinto as executive vice president of global operations. Squinto, in his retirement, will begin chairing the company's new scientific advisory board in January. Release

Stephen Squinto will retire in January.

bluebird bio
James DeTore joined as CFO.


> James DeTore joined bluebird bio ($BLUE) as the company's chief financial officer. He came from Ironwood Pharmaceuticals ($IRWD), where he was vice president of corporate finance, and before that he spent some time at Genzyme. Release

> Cellular Dynamics International ($ICEL) has appointed Susan Willetts to its board of directors. Release

> United Therapeutics ($UTHR) has appointed Katherine Klein to its board of directors as an independent director. Release

> Toni Wayne has joined Epic Sciences as vice president of human resources. Release

> Manish Singh is resigning as chief executive officer of Lion Biotechnologies ($LBIO), effective Dec. 31. Release

> Greer Laboratories has appointed Rick Russell as president and chief executive officer. Release

> Argos Therapeutics ($ARGS) has appointed Philippe Van Holle to the company's board of directors. Release

> Atterocor appointed Dr. Pharis Mohideen as its chief medical officer. Release

> Bone Biologics named Deina Walsh its new CFO. Release

> Lee Wachter joined Charkit as the company's senior vice president of operations. Release

> LABS brought on Sarah Dennison as its vice president of commercial operations. Release

> Graham Vesey stepped down as Regeneus ($RGS) CEO and will take up the position of chief scientific officer. Release

> Retrophin ($RTRX) appointed Stephen Aselage as its CEO. Release

> Alchemia's CEO, Thomas Liquard, left the position. Release


> ViaDerma ($VDRM) has appointed Dr. Andrew Berman as medical director of its advisory board. Release

> Actavis ($ACT) named Maria Teresa Hilado as its chief financial officer. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.